These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24272952)

  • 1. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions.
    Chow AT; Earp JC; Gupta M; Hanley W; Hu C; Wang DD; Zajic S; Zhu M;
    J Clin Pharmacol; 2014 May; 54(5):593-601. PubMed ID: 24272952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.
    Kraynov E; Martin SW; Hurst S; Fahmi OA; Dowty M; Cronenberger C; Loi CM; Kuang B; Fields O; Fountain S; Awwad M; Wang D
    Drug Metab Dispos; 2011 Oct; 39(10):1779-83. PubMed ID: 21768274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
    Evers R; Dallas S; Dickmann LJ; Fahmi OA; Kenny JR; Kraynov E; Nguyen T; Patel AH; Slatter JG; Zhang L
    Drug Metab Dispos; 2013 Sep; 41(9):1598-609. PubMed ID: 23792813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics I: background, concepts, and models.
    Ette EI; Williams PJ
    Ann Pharmacother; 2004 Oct; 38(10):1702-6. PubMed ID: 15328391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
    Ette EI; Williams PJ; Lane JR
    Ann Pharmacother; 2004 Dec; 38(12):2136-44. PubMed ID: 15507495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
    Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
    Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.
    Williams PJ; Ette EI
    Clin Pharmacokinet; 2000 Dec; 39(6):385-95. PubMed ID: 11192472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.
    Baneyx G; Fukushima Y; Parrott N
    Future Med Chem; 2012 Apr; 4(5):681-93. PubMed ID: 22458685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.
    Conner KP; Devanaboyina SC; Thomas VA; Rock DA
    Pharmacol Ther; 2020 Aug; 212():107574. PubMed ID: 32433985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PK-PD modeling of protein drugs: implications in assay development.
    Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
    Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins.
    Kagan L
    Drug Metab Dispos; 2014 Nov; 42(11):1890-905. PubMed ID: 25122564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?
    Zhou H
    J Clin Pharmacol; 2006 Nov; 46(11):1268-89. PubMed ID: 17050792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
    Yu H; Tweedie D
    Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.
    Girish S; Martin SW; Peterson MC; Zhang LK; Zhao H; Balthasar J; Evers R; Zhou H; Zhu M; Klunk L; Han C; Berglund EG; Huang SM; Joshi A
    AAPS J; 2011 Sep; 13(3):405-16. PubMed ID: 21630127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics II: estimation methods.
    Ette EI; Williams PJ
    Ann Pharmacother; 2004 Nov; 38(11):1907-15. PubMed ID: 15367729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    Grime KH; Bird J; Ferguson D; Riley RJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model appropriateness and population pharmacokinetic modeling.
    Ette EI; Williams PJ; Kim YH; Lane JR; Liu MJ; Capparelli EV
    J Clin Pharmacol; 2003 Jun; 43(6):610-23. PubMed ID: 12817524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
    Zhang L; Reynolds KS; Zhao P; Huang SM
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):134-45. PubMed ID: 20045016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.